ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males (Q37299250)

19 August 2017

1 reference

title

ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males (English)

1 reference

19 August 2017

1 reference

C Wang

1

1 reference

19 August 2017

E Nieschlag

2

1 reference

19 August 2017

R Swerdloff

3

1 reference

19 August 2017

H M Behre

4

1 reference

19 August 2017

W J Hellstrom

5

1 reference

19 August 2017

L J Gooren

6

1 reference

19 August 2017

J M Kaufman

7

1 reference

19 August 2017

J-J Legros

8

1 reference

19 August 2017

B Lunenfeld

9

1 reference

19 August 2017

A Morales

10

1 reference

19 August 2017

J E Morley

11

1 reference

19 August 2017

C Schulman

12

1 reference

19 August 2017

I M Thompson

13

1 reference

19 August 2017

W Weidner

14

1 reference

19 August 2017

F C W Wu

15

1 reference

19 August 2017

publication date

16 October 2008

1 reference

International Journal of Impotence Research

19 August 2017

published in

1 reference

19 August 2017

volume

21

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

1-8

1 reference

Prevalence of symptomatic androgen deficiency in men.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Effects of testosterone on sexual function in men: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Investigation, treatment and monitoring of late-onset hypogonadism in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

The relationship between pituitary-gonadal function and sexual behavior in healthy aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

The relationship between libido and testosterone levels in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Blood testosterone threshold for androgen deficiency symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Correlations between hormones, physical, and affective parameters in aging urologic outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

The value of pituitary magnetic resonance imaging in men with hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

A critical evaluation of simple methods for the estimation of free testosterone in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Rate and circumstances of clinical vertebral fractures in older men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Endocrine aspects of sexual dysfunction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Androgen deficiency, diabetes, and the metabolic syndrome in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Aging, androgens, and the metabolic syndrome in a longitudinal study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Ethical issues in urology: the patient's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Risks of testosterone-replacement therapy and recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone replacement therapy after primary treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

The role of testosterone replacement therapy following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone treatment comes of age: new options for hypogonadal men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Testosterone therapy and obstructive sleep apnea: is there a real connection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

Age, Disease, and Changing Sex Hormone Levels in Middle-Aged Men: Results of the Massachusetts Male Aging Study*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Treatment of androgen deficiency in the aging male

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Testosterone Deficiency Syndrome (TDS) needs to be named appropriately--the importance of accurate terminology

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Association of specific symptoms and metabolic risks with serum testosterone in older men

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Validation of a screening questionnaire for androgen deficiency in aging males

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Errors in the measurement of plasma free testosterone

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Salivary testosterone in men: further evidence of a direct correlation with free serum testosterone

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III)

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.41

7 January 2021

Identifiers

DOI

10.1038/IJIR.2008.41

1 reference

Dimensions Publication ID

19 August 2017

1041373846

0 references

1 reference